Search clinical trials for: SHR2150

Total 43 results

Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

HIV-1 Infection

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma
Chinese PLA General Hospital

Unknown

Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects

Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR1258 in Patients With Biliary Tract Cancer

Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects

Healthy Adult Subjects

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Pharmacokinetic Test of High-fat Diet After Oral Administration of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Prostate Cancer | Castration-resistant Prostate Cancer

China
Chinese PLA General Hospital

Recruiting

SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Relapsed or Refractory Hodgkin Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers

Lymphoma

China
Peking University Cancer Hospital & Institute

Recruiting

To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma

Melanoma

China
Chinese PLA General Hospital

Recruiting

Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Lymphoma | Solid Tumor

China
Hengrui Therapeutics, Inc.

Unknown

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Breast Cancer | Gastric Cancer | NSCLC | Solid Tumors

United States
Serodus AS

Recruiting

SER150 vs Placebo in Diabetic Kidney Disease

Diabetic Kidney Disease

Australia, New Zealand
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
Henan Cancer Hospital

Active, not recruiting

Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma

Gastric Cancer

China
Fudan University

Recruiting

Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer (MULAN)

Breast Cancer | Metastatic Cancer

China
Yanqiao Zhang
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC (HZ-T-PD1-APA)

Hepatocellular Carcinoma
Peking University

Unknown

PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma

NK/T-cell Lymphoma
Qilu Hospital of Shandong University

Recruiting

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Unknown

PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma

Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Drug-drug Interaction Study of SHR2150 on Healthy Chinese Volunteers

Human Immunodeficiency Virus Infection

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)

Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

China
Ruijin Hospital

Recruiting

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Peripheral T Cell Lymphoma

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Hunan Cancer Hospital
Suzhou Sheng Diya Biomedical Co., Ltd.

Active, not recruiting

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

Adenocarcinoma of the Lung

China
Sangart

Completed

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

Vascular Disease | Critical Lower Limb Ischemia

Sweden
Fudan University

Active, not recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER)

TNBC - Triple-Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Non-squamous Non-small-cell Lung Cancer

China
Fudan University

Recruiting

FUSCC Refractory TNBC Umbrella (FUTURE) (FUTURE)

Triple-negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects

Healthy Adult Subjects

China
Sun Yat-sen University

Recruiting

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Persistent Cervical Cancer

China
Fudan University

Not yet recruiting

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

TNBC - Triple-Negative Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Fluconazole on Pharmacokinetics of SHR2554 in Healthy Subjects

Malignant Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects

Healthy

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer | Breast Neoplasm | HER2-negative Breast Cancer | Hormone Receptor Positive Tumor

China
Guangdong Association of Clinical Trials
Chinese Thoracic Oncology Group

Recruiting

Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)

Carcinoma, Non-Small-Cell Lung

China

Search clinical trials for: SHR2150

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations